| 1 |
NCT00970970 |
Completed |
Visualizing Vascular Endothelial Growth Factor (VEGF) Producing Lesions in Von Hippel-Lindau Disease |
- Von Hippel-Lindau Disease
- Hemangioblastoma
- Renal Cell Carcinoma
- (and 2 more...)
|
- Other: 89Zr bevacizumab PET scan
|
Observational |
|
- University Medical Center Groningen
- VHL Family Alliance
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Detection rate of VHL associated lesions with 89Zr-bevacizumab PET scans in patients with VHLD
- Progressive lesions within 12 months, defined as new lesions or lesions that show an increase in size of at least 5% of the longest diameter on MRI, or lesions that become symptomatic
|
22 |
All |
18 Years and older (Adult, Senior) |
NCT00970970 |
METc2009.119 |
VHLimage |
September 2009 |
November 2012 |
November 2012 |
September 3, 2009 |
November 6, 2012 |
|
- University Medical Center Groningen
Groningen, Netherlands
|
| 2 |
NCT02108002 |
Enrolling by invitation |
Effect of Vorinostat on Nervous System Hemangioblastomas in Von Hippel-Lindau Disease (Missense Mutation Only) |
- Von Hippel-Lindau Disease
|
|
Interventional |
Phase 1 |
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- The presence and quantity of mutant VHL protein in resected hemangioblastoma specimens, including comparison of specimens without vorinostat treatment and those with presurgical vorinostat treatment.
|
7 |
All |
18 Years and older (Adult, Senior) |
NCT02108002 |
140067
14-N-0067 |
|
April 5, 2014 |
December 1, 2018 |
December 31, 2018 |
April 9, 2014 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 3 |
NCT01168440 |
Completed |
Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease |
- Von Hippel-Lindau Disease
|
|
Interventional |
Phase 2 |
- Association Pour La Recherche des Thérapeutiques Innovantes en Cancérologie
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Objective response rate (RECIST criteria)
- Safety and tolerability (NCI-CTC criteria Version 3.0).
- Time-to-event endpoints: overall survival, time to disease progression, progression free survival, time to response and duration of response.
- Quality of life in VHL patients receiving sunitinib.
|
5 |
All |
18 Years to 90 Years (Adult, Senior) |
NCT01168440 |
VHLSUT09 |
VHLSUT |
March 2010 |
February 2011 |
February 2011 |
July 23, 2010 |
September 13, 2012 |
|
- Hospital Saint André - Service de cancérologie
Bordeaux, France - Hopital Kremlin-Bicêtre
Kremlin-Bicêtre, France - Hôpital Européen Georges Pompidou - Service d'Oncologie Médicale
Paris, France
|
| 4 |
NCT00673816 |
Terminated
Has Results |
Sunitinib Malate to Treat Advanced Eye Disease in Patients With Von Hippel-Lindau Syndrome |
- Von Hippel-Lindau Syndrome
|
|
Interventional |
Phase 1
Phase 2 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Change in Best Corrected Visual Acuity (BCVA) From Baseline to Week 36
- Change in Retinal Thickness From Baseline to Week 36
- Change in Retinal Angioma Leakage From Baseline to Week 36
|
2 |
All |
18 Years and older (Adult, Senior) |
NCT00673816 |
080129
08-EI-0129 |
VHL3 |
May 2008 |
February 2011 |
February 2011 |
May 7, 2008 |
December 19, 2011 |
December 19, 2011 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 5 |
NCT00062166 |
Completed |
Natural History and Management of Pancreatic Lesions in Von Hippel-Lindau Disease |
- Von Hippel-Lindau Disease
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- To identify patients with VHL having pancreatic lesions defined by simple cysts, microcystic adenomas, neuroendocrine tumors and other solid lesions of the pancreas.
- To obtain blood samples from patients to determine VHL mutation status and subtype the mutations for potential correlation with disease severity.
- When possible, to obtain tissue from pancreatic lesions for genetic analysis including CGH, tissue proteomics, and cDNA microarray analysis.
|
340 |
All |
12 Years to 80 Years (Child, Adult, Senior) |
NCT00062166 |
030145
03-C-0145 |
|
April 11, 2003 |
|
November 29, 2017 |
June 6, 2003 |
December 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 6 |
NCT00001803 |
Active, not recruiting |
Von Hippel-Lindau Disease Genetic Epidemiology Study |
- Von Hippel Lindau Disease
- Kidney Neoplasms
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Case-Control
- Time Perspective: Retrospective
|
- To relate the expression of VHL tumors to lifestyle factors (tobacco & alcohol use, physical activity), occupational exposures, reproductive and hormonal factors, demographic factors, medication use, diet, and putative susceptibility gen...
|
546 |
All |
13 Years to 100 Years (Child, Adult, Senior) |
NCT00001803 |
990053
99-C-0053 |
|
February 26, 1999 |
|
|
November 4, 1999 |
February 23, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 7 |
NCT02207686 |
Unknown † |
Assessment of Residual VHL Function in Tumors - Can it Predict the Patients' Individual Course of Disease? |
- Von Hippel-Lindaus Disease
|
|
Observational |
|
- Marie Luise Bisgaard, MD
- University of Copenhagen
|
Other |
- Observational Model: Cohort
- Time Perspective: Retrospective
|
- Residual pVHL activity measured by amount of VHL mRNA in tumor cells
- Presence of VHL protein (pVHL) in tumor cells
- Type of second hit (somatic mutation) found in DNA from tumor cells
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT02207686 |
H-2-2010-012-A |
|
September 2014 |
August 2016 |
August 2017 |
August 4, 2014 |
November 13, 2015 |
|
- Department of Cellular and Molecular Medicine, University of Copenhagen
Copenhagen, Copenhagen N, Denmark
|
| 8 |
NCT02420067 |
Recruiting |
Screening for Endolymphatic Sac Tumours (ELSTs) in Von Hippel-Lindau (vHL) Patients |
- Von Hippel-Lindau Disease
|
|
Observational |
|
- Marie Luise Bisgaard, MD
- Rigshospitalet, Denmark
- St Thomas' Hospital, London
- (and 5 more...)
|
Other |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- In each ear: development of an ELST during the study period correlated to baseline hearing level.
- In each ear: development of an ELST during the study period correlated to hearing level at two year follow-up.
- In each ear: development of an ELST during the study period correlated to hearing level at five year follow-up.
- (and 9 more...)
|
380 |
All |
15 Years and older (Child, Adult, Senior) |
NCT02420067 |
H-A-2007-0125, A |
|
February 2011 |
December 2017 |
December 2026 |
April 17, 2015 |
May 9, 2017 |
|
- Department of Cellular and Molecular Medicine, University of Copenhagen
Copenhagen, Copenhagen N, Denmark
|
| 9 |
NCT00088374 |
Completed
Has Results |
17AAG to Treat Kidney Tumors in Von Hippel-Lindau Disease |
- Hippel-Lindau Disease
- Kidney Cancer
|
- Drug: 17 allylamino-17-demethoxygeldanamycin
- Drug: 18 FDG (Fludeoxyglucose 18F)
- Drug: [15-O] H2O
- Drug: EPL diluent
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Renal Tumor Response
- Number of Participants With a Non-renal Tumor Response
- The Number of Participants With Adverse Events
- (and 3 more...)
|
9 |
All |
18 Years and older (Adult, Senior) |
NCT00088374 |
040238
04-C-0238 |
|
July 2004 |
January 2009 |
January 2009 |
July 26, 2004 |
July 27, 2012 |
September 29, 2011 |
- National Cancer Institute, National Institutes of Health
Bethesda, Maryland, United States
|
| 10 |
NCT00330564 |
Terminated
Has Results |
Evaluation of Sunitinib Malate in Patients With Von Hippel-Lindau Syndrome (VHL) Who Have VHL Lesions to Follow |
- Von Hippel-Lindau Syndrome
- Renal Cell Carcinoma
- Hemangioblastoma
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Pfizer
|
Other / Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety of Sunitinib Administration in Participants With Von Hippel-Lindau Syndrome (VHL)
- Number of VHL Lesion Complete + Partial Responses
|
15 |
All |
18 Years and older (Adult, Senior) |
NCT00330564 |
2005-0463 |
|
May 2006 |
May 2011 |
May 2011 |
May 29, 2006 |
February 27, 2012 |
June 30, 2011 |
- UT MD Anderson Cancer Center
Houston, Texas, United States
|
| 11 |
NCT01436227 |
Active, not recruiting |
Pazopanib in Von Hippel-Lindau (VHL) Syndrome |
- Von Hippel-Lindau Syndrome
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- RECIST Overall Response (OR) Rate = Number of Participants with Complete Response and Partial Response (CR+PR) at 24 weeks
|
32 |
All |
18 Years and older (Adult, Senior) |
NCT01436227 |
2011-0465
NCI-2011-03285 |
|
January 2012 |
January 2019 |
January 2019 |
September 19, 2011 |
September 20, 2017 |
|
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 12 |
NCT00052013 |
Completed |
Treatment of Von Hippel-Lindau (VHL)-Related Hemangioblastoma With PTK787/ZK 222584 |
- Von Hippel-Lindau Disease
- CNS Hemangioblastoma
- Retinal Hemangioblastoma
|
|
Interventional |
Phase 2 |
- Novartis Pharmaceuticals
- Novartis
|
Industry |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Evaluate efficacy
- Evaluate changes in dynamic contrast enhanced magnetic resonance imaging
- To explore the correlation of the pharmacokinetics
- To assess changes in surrogate markers of angiogenesis
|
11 |
All |
18 Years and older (Adult, Senior) |
NCT00052013 |
CPTK787 0144 |
|
February 2003 |
June 2006 |
|
January 22, 2003 |
March 6, 2017 |
|
- Dana Farber Cancer Institute
Boston, Massachusetts, United States - Duke University Medical Center
Durham, North Carolina, United States
|
| 13 |
NCT01015300 |
Terminated |
Bevacizumab (Avastin) in Unresectable/Recurrent Hemangioblastoma From Von-Hippel-Lindau Disease |
- Hemangioblastomas
- Von Hippel Lindau Disease
|
|
Interventional |
Early Phase 1 |
- Dartmouth-Hitchcock Medical Center
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Radiographic response in the size of the hemangioblastoma on magnetic resonance imaging (MRI)
- Changes in VEGF with bevacizumab treatment assist in the predication of radiographic response. Products of the HIF-1A synthesis pathway: plasma VEGF, PDGF, TGF-a and erythropoietin.
|
1 |
All |
18 Years and older (Adult, Senior) |
NCT01015300 |
D0904 |
|
December 2009 |
October 2011 |
April 2012 |
November 18, 2009 |
May 11, 2012 |
|
- Dartmouth Hitchcock Medical Center
Lebanon, New Hampshire, United States
|
| 14 |
NCT02859441 |
Recruiting |
A Phase I/II Trial for Intravitreous Treatment of Severe Ocular Von Hippel-Lindau Disease Using a Combination of the PDGF Antagonist E10030 and the VEGF Antagonist Ranibizumab |
- Von Hippel-Lindau Syndrome
|
- Drug: Ranibizumab
- Drug: E10030
|
Interventional |
Phase 1
Phase 2 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Tabulation of adverse events
- The proportion of participants experiencing reduction in size of at least one RCH, in the absence of other ablative treatment (assessed by fundus photography and fluorescein angiography [FA])
- Proportion of participants undergoing ablative treatment of RCH or ocular surgery
- (and 7 more...)
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT02859441 |
160159
16-EI-0159 |
|
August 6, 2016 |
August 31, 2018 |
August 31, 2018 |
August 9, 2016 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 15 |
NCT00056199 |
Completed |
EYE001 to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
|
|
Interventional |
Phase 1 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
5 |
All |
Child, Adult, Senior |
NCT00056199 |
030101
03-EI-0101 |
|
March 2003 |
|
November 2005 |
March 7, 2003 |
March 4, 2008 |
|
- National Eye Institute (NEI)
Bethesda, Maryland, United States
|
| 16 |
NCT01266070 |
Terminated
Has Results |
TKI 258 in Von Hippel-Lindau Syndrome (VHL) |
- Von Hippel-Lindau Syndrome
|
|
Interventional |
Phase 2 |
- M.D. Anderson Cancer Center
- Novartis
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Most Frequent & Most Serious Adverse Events: Safety of Dovitinib for 6 Months
- Number of VHL Participants With Response at 6 Months
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT01266070 |
2010-0650
NCI-2011-00305 |
|
November 2012 |
December 2015 |
December 2015 |
December 24, 2010 |
February 13, 2017 |
February 13, 2017 |
- University of Texas MD Anderson Cancer Center
Houston, Texas, United States
|
| 17 |
NCT00089765 |
Completed |
Ranibizumab Injections to Treat Retinal Tumors in Patients With Von Hippel-Lindau Syndrome |
- Von Hippel-Lindau Syndrome
|
|
Interventional |
Phase 1 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Primary Purpose: Treatment
|
|
5 |
All |
18 Years and older (Adult, Senior) |
NCT00089765 |
040240
04-EI-0240 |
|
August 10, 2004 |
|
August 15, 2007 |
August 13, 2004 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 18 |
NCT03108066 |
Active, not recruiting |
PT2385 for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma |
- VHL Gene Mutation
- VHL
- VHL Syndrome
- (and 8 more...)
|
|
Interventional |
Phase 2 |
- Peloton Therapeutics, Inc.
- National Institutes of Health (NIH)
|
Industry / NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate (ORR)
- Progression Free Survival (PFS)
- Duration of Response (DOR)
- Time to Response (TTR)
|
4 |
All |
18 Years and older (Adult, Senior) |
NCT03108066 |
PT2385-202 |
|
May 10, 2017 |
April 2022 |
September 2022 |
April 11, 2017 |
August 24, 2017 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 19 |
NCT00005902 |
Active, not recruiting |
Study of Brain and Spinal Cord Tumor Growth and Cyst Development in Patients With Von Hippel Lindau Disease |
- Hemangioblastoma
- Hippel Lindau Disease
|
|
Observational |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
250 |
All |
8 Years to 75 Years (Child, Adult, Senior) |
NCT00005902 |
000140
00-N-0140 |
|
June 5, 2000 |
|
|
June 7, 2000 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 20 |
NCT00075348 |
Completed |
Genetic Study to Identify Gene Mutations in Participants Previously Enrolled in Clinical Trial NCI-99-C-0053 Who Have Von Hippel-Lindau Syndrome or Are at Risk for Von Hippel-Lindau Syndrome |
- Kidney Cancer
- Von Hippel-lindau Syndrome
|
- Genetic: mutation analysis
|
Observational |
|
- National Institutes of Health Clinical Center (CC)
- National Cancer Institute (NCI)
|
NIH |
|
|
260 |
All |
18 Years and older (Adult, Senior) |
NCT00075348 |
030148
03-C-0148
CDR0000302478 |
|
December 2003 |
December 2008 |
December 2008 |
January 12, 2004 |
March 15, 2012 |
|
- Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office
Bethesda, Maryland, United States
|
| 21 |
NCT03401788 |
Recruiting |
A Phase 2 Study of PT2977 for the Treatment of Von Hippel Lindau Disease-Associated Renal Cell Carcinoma |
- VHL - Von Hippel-Lindau Syndrome
- VHL
- VHL Gene Mutation
- (and 4 more...)
|
|
Interventional |
Phase 2 |
- Peloton Therapeutics, Inc.
|
Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rate (ORR)
- Duration of response (DOR)
- Time to response (TTR)
- (and 2 more...)
|
50 |
All |
18 Years and older (Adult, Senior) |
NCT03401788 |
PT2977-202 |
|
March 20, 2018 |
March 1, 2020 |
March 1, 2023 |
January 17, 2018 |
March 22, 2018 |
|
- Yale Cancer Center
New Haven, Connecticut, United States - National Institutes of Health Clinical Center
Bethesda, Maryland, United States - Massachusetts General Hospital
Boston, Massachusetts, United States - (and 7 more...)
|
| 22 |
NCT00001668 |
Completed |
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors |
- Deafness
- Kidney Diseases
- Kidney Neoplasms
- (and 2 more...)
|
|
Observational |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
|
75 |
All |
Child, Adult, Senior |
NCT00001668 |
970102
97-N-0102 |
|
April 1997 |
|
April 2000 |
December 10, 2002 |
March 4, 2008 |
|
- National Institute of Neurological Disorders and Stroke (NINDS)
Bethesda, Maryland, United States
|
| 23 |
NCT00566995 |
Completed
Has Results |
Phase II Study of Vandetanib in Individuals With Kidney Cancer |
- Renal Cancer
- Von Hippel Lindau
|
- Drug: ZACTIMA (Vandetanib) (ZD6474)
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall Response Rate.
- Number of Participants With Adverse Events
|
37 |
All |
18 Years and older (Adult, Senior) |
NCT00566995 |
080020
08-C-0020 |
|
November 2007 |
June 2014 |
March 2015 |
December 4, 2007 |
April 7, 2015 |
March 11, 2015 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 24 |
NCT02120040 |
Unknown † |
Psychosocial Consequences of the Screening of Von Hippel Lindau Diseases for Patients Operated for a hémangioblastoma of Nervous Centrasl System |
- Hemangioblastoma (HB) of the Central Nervous System (CNS)
|
- Other: evaluation of anxiety with psychosocial scales
|
Interventional |
Not Applicable |
- Assistance Publique Hopitaux De Marseille
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
|
- evaluate the impact on anxiety of VHL mutation screening of patients operated for HB
- assessment of the mood
|
42 |
All |
18 Years to 80 Years (Adult, Senior) |
NCT02120040 |
2014-01 |
PsychoVHL |
May 2014 |
September 2016 |
December 2016 |
April 22, 2014 |
November 17, 2015 |
|
- Assistance Publique Hopitaux de Marseille
Marseille, France
|
| 25 |
NCT00001703 |
Terminated
Has Results |
Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With Renal Cell Carcinoma |
|
- Biological: incomplete Freund's adjuvant
- Biological: von Hippel-Lindau peptide vaccine
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Percentage of Participants Who Generated an Immune Response
- The Number of Participants With Adverse Events.
|
6 |
All |
18 Years and older (Adult, Senior) |
NCT00001703 |
980139
98-C-0139 |
|
August 1998 |
November 2008 |
November 2008 |
November 4, 1999 |
July 25, 2014 |
June 14, 2012 |
- National Cancer Institute, National Institutes of Health
Bethesda, Maryland, United States
|
| 26 |
NCT01967537 |
Active, not recruiting |
Evaluation of 68Gallium-DOTATATE PET/CT for Detecting Neuroendocrine Tumors |
- Neuroendocrine Tumors
- Von Hippel-Lindau Syndrome
- Hippel-Lindau Disease
|
- Drug: 68Gallium DOTATATE
- Procedure: Radio-guided surgery
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- To determine the accuracy of 68Gallium-DOTATATE PET/CT scans in detecting unknown primary and metastatic gastrointestinal and pancreatic neuroendocrine tumors
- To evaluate 68Gallium-DOTATATE uptake in NETs and its association with tumor differentiation.
- To determine whether 68Gallium-DOTATATE uptake value is predictive of tumor growth and/or disease progression.
- (and 2 more...)
|
337 |
All |
10 Years to 99 Years (Child, Adult, Senior) |
NCT01967537 |
130193
13-C-0193 |
|
October 18, 2013 |
December 17, 2017 |
December 3, 2022 |
October 23, 2013 |
February 14, 2018 |
|
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
|
| 27 |
NCT00602862 |
Completed |
Effect of Sorafenib on ccRCC Uptake of Radiolabeled Bevacizumab or cG250 |
- Clear Cell Renal Cell Carcinoma
|
- Drug: Sorafenib
- Drug: 111Indium-bevacizumab
- Drug: 111Indium-cG250
|
Interventional |
Not Applicable |
- Radboud University
- Dutch Cancer Society
|
Other |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Basic Science
|
- To determine the effect of sorafenib treatment on 111In-cG250 uptake of the tumor
- To determine the effect of sorafenib treatment on 111In-bevacizumab uptake of the tumor
- Immunohistochemical analysis of CA-IX expression, (p)VHL status, HIF1-a, VEGF and PDGF expression, apoptosis and necrosis of surgical specimen
|
26 |
All |
18 Years and older (Adult, Senior) |
NCT00602862 |
Sorafenib-mAbs |
|
July 2007 |
April 2012 |
June 2012 |
January 28, 2008 |
December 2, 2013 |
|
- Radboud University Nijmegen Medical Center
Nijmegen, Gelderland, Netherlands
|
| 28 |
NCT00385333 |
Completed |
Metabolic Mapping to Measure Retinal Metabolism |
- Macular Degeneration
- Diabetic Retinopathy
- Hippel-Landau Disease
- Mitochondria
|
- Procedure: Feasibility Study - Imaging System
|
Interventional |
Phase 2 |
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Fluorescence anisotropy
- The difference in fluorescence anisotropy values within subjects under room air and 100% oxygen exposure (one minute exposure time).
|
28 |
All |
18 Years and older (Adult, Senior) |
NCT00385333 |
060252
06-EI-0252 |
|
September 29, 2006 |
June 1, 2008 |
September 16, 2010 |
October 9, 2006 |
July 2, 2017 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 29 |
NCT01730755 |
Available |
Ruxolitinib for Chuvash Polycythemia |
- Erythrocytosis, Familial, 2
|
|
Expanded Access |
|
- Washington University School of Medicine
- Incyte Corporation
|
Other / Industry |
|
|
|
All |
Child, Adult, Senior |
NCT01730755 |
I-RUX-12-03 |
|
|
|
|
November 21, 2012 |
January 8, 2016 |
|
- Washington University School of Medicine
St. Louis, Missouri, United States
|
| 30 |
NCT01372813 |
Terminated
Has Results |
Vandetanib to Treat Advanced Kidney Cancer |
- Advanced Clear Cell Renal Carcinoma
|
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Number of Participants With a Clinical Response (Partial Response (PR) + Clinical Response (CR))
- Effect of Vandetanib on Plasma Biomarkers-vascular Endothelial Growth Factor (VEGF), Vascular Endothelial Growth Factor 2 (VEGFR2)
- Number of Circulating Endothelial Progenitor Cells (CEP) Per 10^6 Mononuclear Cells or Per Microliter of Peripheral Blood Analyzed in Samples Taken Before and After Treatment
- (and 7 more...)
|
3 |
All |
18 Years and older (Adult, Senior) |
NCT01372813 |
080039
08-C-0039 |
|
December 2007 |
June 2010 |
June 2010 |
June 14, 2011 |
October 23, 2015 |
March 12, 2012 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 31 |
NCT01538238 |
Completed |
pazopanib_NCRCC,Ph2 STUDY |
- Locally Advanced or Metastatic Non-clear Cell Type Renal Cell Carcinoma
|
|
Interventional |
Phase 2 |
|
Other |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Overall response rates
- Progression-free survival
- Overall survival
- (and 2 more...)
|
10 |
All |
19 Years and older (Adult, Senior) |
NCT01538238 |
2012-01-056 |
|
May 2, 2012 |
February 28, 2015 |
November 14, 2015 |
February 24, 2012 |
April 26, 2017 |
|
- Samsung medical Center
Seoul, Korea, Republic of
|
| 32 |
NCT00102544 |
Recruiting |
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures |
- Adenocarcinoma
- Prostate Neoplasms
- Prostate Cancer
- (and 2 more...)
|
|
Interventional |
Phase 3 |
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Feasibility of using electromagnetic devices in different cohorts.
- Success of ablation as determined by imaging
|
3195 |
All |
18 Years to 100 Years (Adult, Senior) |
NCT00102544 |
050091
05-CC-0091 |
|
January 27, 2005 |
January 15, 2020 |
January 2, 2022 |
January 31, 2005 |
March 29, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 33 |
NCT01496625 |
Recruiting |
National Eye Institute Biorepository for Retinal Diseases |
- Age-Related Macular Degeneration
- Diabetic Retinopathy
- Von Hippel-Lindau Syndrome
- (and 2 more...)
|
|
Observational |
|
- National Eye Institute (NEI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Interaction of key parameters of phenotype (like visual acuity, retinal features on ocular imaging) with genetic variants and other biomarkers identified from biospecimens; and characterization of new experimental models of eye health and di...
|
2300 |
All |
Child, Adult, Senior |
NCT01496625 |
120042
12-EI-0042 |
|
December 1, 2011 |
|
|
December 21, 2011 |
April 4, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 34 |
NCT01712685 |
Terminated
Has Results |
Imaging Studies of Kidney Cancer Using 18F-VM4-037 |
- Carcinoma, Renal Cell
- Kidney Neoplasms
|
- Drug: 18F-VM4-037
- Procedure: PET/CT
|
Interventional |
Phase 2 |
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
|
- Level of Uptake of 18F-VM4-037 in Tumor and Non Tumor Tissues, Calculated as Standardized Uptake Values (SUVs)
- Number of Participants With Adverse Events
- Mean Standard Uptake Value (SUV) for All Target Lesions
- (and 6 more...)
|
12 |
All |
18 Years and older (Adult, Senior) |
NCT01712685 |
130018
13-C-0018 |
|
October 2012 |
August 2013 |
August 2013 |
October 23, 2012 |
January 11, 2017 |
September 19, 2014 |
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 35 |
NCT00001238 |
Recruiting |
Clinical Manifestations and Molecular Bases of Heritable Urologic Malignant Disorders |
- Kidney Cancer
- Urologic Malignant Disorders
|
|
Observational |
|
- National Cancer Institute (NCI)
- National Institutes of Health Clinical Center (CC)
|
NIH |
- Observational Model: Cohort
- Time Perspective: Prospective
|
- Characterize the natural and clinical histories of inherited urologic malignant disorders.
- Determine the genetic etiology of hereditary urologic malignant disorders in which the gene defect is unknown, by linkage analysis, positional cloning and evaluation of candidate genes.
- Correlate specific mutations and their associated protein domains with disease phenotypic expression based on parameters including presenting age, clinical manifestations, histopathology and rate of recurrence.
- Identify and describe as yet unknown or uncharacterized inherited urologic malignant disorders.
|
5000 |
All |
2 Years to 100 Years (Child, Adult, Senior) |
NCT00001238 |
890086
89-C-0086 |
|
April 20, 1989 |
|
|
November 4, 1999 |
April 2, 2018 |
|
- National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
| 36 |
NCT00470977 |
Completed |
Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy |
- Coats' Disease
- Idiopathic Retinal Telangiectasia
- Retinal Angiomatous Proliferation
- (and 7 more...)
|
- Drug: ranibizumab injection (0.5 mg)
|
Interventional |
Phase 1
Phase 2 |
- Manhattan Eye, Ear & Throat Hospital
- Genentech, Inc.
|
Other / Industry |
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Safety and tolerability of intravitreal injections of ranibizumab in the treatment of non-AMD variants and other CNV related conditions
- Mean change in central retinal thickness as measured by OCT at month 12 compared to baseline
- Change in leakage area seen during fluorescein angiography at month 12 as compared with baseline
- Number of additional injections required following the initial 3 injections
|
18 |
All |
18 Years and older (Adult, Senior) |
NCT00470977 |
Protocol: FVF4140S |
FVF4140S |
May 2007 |
December 2010 |
December 2010 |
May 8, 2007 |
October 25, 2012 |
|
- Lenox Hill Hospital/Manhattan Eye Ear and Throat Institute
New York, New York, United States - Lenox Hill Hospital/Manhattan Eye, Ear & Throat Institute
New York, New York, United States
|
| 37 |
NCT03050268 |
Recruiting |
Familial Investigations of Childhood Cancer Predisposition |
- Acute Leukemia
- Adenomatous Polyposis
- Adrenocortical Carcinoma
- (and 43 more...)
|
|
Observational |
|
- St. Jude Children's Research Hospital
|
Other |
- Observational Model: Family-Based
- Time Perspective: Prospective
|
- Identification of novel cancer predisposing genes
|
3000 |
All |
Child, Adult, Senior |
NCT03050268 |
SJFAMILY |
SJFAMILY |
April 6, 2017 |
March 31, 2037 |
March 31, 2037 |
February 10, 2017 |
January 5, 2018 |
|
- St. Jude Children's Research Hospital
Memphis, Tennessee, United States
|
| 38 |
NCT01865747 |
Active, not recruiting
Has Results |
A Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma |
|
- Drug: Cabozantinib tablets
- Drug: Everolimus (Afinitor) tablets
|
Interventional |
Phase 3 |
|
Industry |
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
|
- Progression-free Survival (PFS)
- Overall Survival (OS)
- Objective Response Rate (ORR)
|
658 |
All |
18 Years and older (Adult, Senior) |
NCT01865747 |
XL184-308 |
METEOR |
June 2013 |
May 22, 2015 |
December 2017 |
May 31, 2013 |
July 18, 2017 |
July 18, 2017 |
- Birmingham, Alabama, United States
- Anchorage, Alaska, United States
- Gilbert, Arizona, United States
- (and 202 more...)
|
| 39 |
NCT00004847 |
Recruiting |
Diagnosis of Pheochromocytoma |
|
|
Observational |
|
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institutes of Health Clinical Center (CC)
|
NIH |
|
- To investigate the use of radiopharmaceutical tracer, F(18)-FLT for PET/CT scan in evaluating cellular proliferative behavior of various genetically inherited and sporadic pheochromocytomas and paragagliomas in adult patients.
|
2400 |
All |
7 Years and older (Child, Adult, Senior) |
NCT00004847 |
000093
00-CH-0093 |
|
March 1, 2000 |
|
|
March 3, 2000 |
March 29, 2018 |
|
- Johns Hopkins University
Baltimore, Maryland, United States - National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States
|
Create an RSS feed from your search for:
Download the search results for: